References
- Parkin, D.M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55, 74–108.
- Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T.F., Galle, P.R., Seitz, J.F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359, 378–390.
- Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., Luo, R., Feng, J., Ye, S., Yang, T.S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W.Y., Pan, H., Burock, K., Zou, J., Voliotis, D., Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10, 25–34.
- Kim, J.E., Ryoo, B.Y., Ryu, M.H., Chang, H.M., Suh, D.J., Lee, H.C., Lim, Y.S., Kim, K.M., Kang, Y.K. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011, Online First™, 29 March 2011.
- Marrero, J.A. Global Investigation of Therapeutic Decisions In Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than1500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011, 29:256S. Abstract 4001.
- Palozzo, A.C. An Italian model to evaluate appropriateness and effectiveness. European J Hosp Pharm Pract. 2010, 16,54–55.
- Duffaud, F., Therasse, P. [New guidelines to evaluate the response to treatment in solid tumors]. Bull Cancer 2000, 87, 881–886.
- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60, 646–649.
- National Institute for Clinical Excellence, Sorafenib for the treatment of advanced hepatocellular carcinoma, NICE technology appraisal guidance, May 2010.